Teva Pharmaceutical Industries (TEVA) Non-Current Deferred Tax Liability (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $289.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deferred Tax Liability fell 34.32% year-over-year to $289.0 million; the trailing twelve-month figure through Jun 2026 stood at $289.0 million (down 34.32% YoY), and the FY2025 full-year result was $296.0 million, down 38.72% from the prior year.
• Non-Current Deferred Tax Liability grew to $289.0 million in Q2 2026 per TEVA's latest filing, from $273.0 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $666.0 million in Q1 2022 and bottomed at $273.0 million in Q1 2026.
• Historically, Non-Current Deferred Tax Liability has averaged $488.0 million across 5 years, with a median of $533.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability sank 44.73% in 2022, then gained 10.58% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $548.0 million in 2022, then rose by 10.58% to $606.0 million in 2023, then slipped by 20.3% to $483.0 million in 2024, then tumbled by 38.72% to $296.0 million in 2025, then dropped by 2.36% to $289.0 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $289.0 million, $273.0 million, and $296.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.